The story
On April 28, 2005, the US Food and Drug Administration approved exenatide, sold as Byetta, for type 2 diabetes. It was the first drug to copy a gut hormone called GLP-1 (glucagon-like peptide-1), which the intestine releases after a meal. GLP-1 prompts the pancreas to release insulin only when blood sugar is high, slows the emptying of the stomach and signals fullness to the brain. The natural hormone is broken down in a few minutes by an enzyme, DPP-4, so it is useless as a medicine. Exenatide is a synthetic version of exendin-4, a similar molecule found in the saliva of the Gila monster, a venomous lizard of the American Southwest, that resists breakdown and lasts for hours.
The path began in the 1980s when researchers showed that GLP-1 stimulated insulin, and in 1992 endocrinologist John Eng at a Bronx veterans' hospital identified exendin-4 in Gila monster venom. Amylin Pharmaceuticals and Eli Lilly developed it, building on the earlier era of recombinant proteins such as insulin. Patients injected exenatide twice a day. It was modest in effect, but patients lost weight, which prompted interest in stronger and longer-acting versions: liraglutide in 2010, and semaglutide, which was approved for diabetes in 2017 and for obesity in 2021.
Why it mattered
- Longer-acting GLP-1 drugs such as liraglutide and semaglutide followed, which became hugely popular for weight loss.
- Obesity became treatable with drugs in a way that earlier medicines had not allowed.
- Evidence emerged that GLP-1 drugs reduce heart attacks and strokes in people at risk.
- The drugs have strained health budgets and supply chains while raising questions about long-term use.
Sources
- AWARDEE: John Eng (Golden Goose Award) Golden Goose Award
- GLP-1 receptor agonists in the treatment of type 2 diabetes PubMed Central
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…